대한한의학방제학회지 (Herbal Formula Science)

  • 제28권4호
  • /
  • Pages.429-441
  • /
  • 2020
  • /
  • 1229-1218(pISSN)
  • /
  • 2288-5641(eISSN)
대한한의학방제학회 (The Korean Medicine Society for the Herbal Formula Study)
권호 표지
DOI QR코드

DOI QR Code

전신경화증의 한약치료에 대한 국내외 연구 동향

Review of Research for Herbal Medicine on Systemic Sclerosis

  • 노종성 (대구한의대학교 한의과대학 방제학교실) ;
  • 김상찬 (대구한의대학교 한의과대학 방제학교실) ;
  • 변성희 (대구한의대학교 한의과대학 방제학교실) ;
  • 윤미정 (목원대학교 의생명.보건학부) ;
  • 신순식 (동의대학교 한의과대학 방제학교실) ;
  • 손동현 (부산대학교 의과대학 미생물학 및 면역학교실)
  • Roh, Jong Seong (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University) ;
  • Kim, Sang Chan (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University) ;
  • Byun, Sung Hui (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University) ;
  • Yoon, Michung (Division of Medical Engineering and Health Management, Mok-Won University) ;
  • Shin, Soon Shik (Department of Formula Sciences, College of Korean Medicine, Dong-Eui University) ;
  • Sohn, Dong Hyun (Department of Microbiology and Immunology, Pusan National University School of Medicine)
  • 투고 : 2020.11.11
  • 심사 : 2020.11.25
  • 발행 : 2020.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : Systemic sclerosis(SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs and vasculopathy. The purpose of this study was to investigate the trend in the research on SSc using herbal medicine. Methods : We searched for papers which had both systemic sclerosis and herbal medicine from Pubmed, KCI and NDSL. After searching papers, we classified according to the study design and analyzed selected studies. Results : 18 studies were searched. The types and numbers of study were as follows: 11 were in vitro or in vivo studies using herbal medicine or active components, and 7 were clinical research including case reports. 1. Herbal medicines include the therapeutic effects of "tonifying qi(補氣)" or "active blood(活血)" improved systemic sclerosis in vivo and in vitro studies. 2. Active components isolated from Herbal Medicine such as Astragalus membranaceus(黃芪), Zhizi(梔子), Salvia miltiorrhiza(丹蔘) have anti-fibrotic effects. 3. Clinical trials showed that herbal medicine can improve the symptom of systemic sclerosis including skin fibrosis, Raynaud's phenomenon, pain and gastric dysmotility. Conclusions : This study showed that herbal medicine can be effective for treating SSc. However, further studies are needed to develop novel medicine for SSc.

키워드

참고문헌

  1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-99. https://doi.org/10.1016/S0140-6736(17)30933-9
  2. Brown M, O'Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310-21.
  3. Su M, Tian F, Ouyang B, Wu X, Guo F, Chen H, et al. Bufei Qingyu Granules Inhibit the Development of Systemic Sclerosis via Notch-1/Jagged-2 Signaling Pathway. Evid Based Complement Alternat Med. 2019;2019:6709278.
  4. Bian H, Fan YS, Lou LH, Mao BY, Shi JY. [Effect of Wenyang Huazhuo Tongluo recipe contained serum on proliferation and cell cycle of systemic sclerosis skin fibroblasts]. Zhong Yao Cai. 2009;32(6):936-9.
  5. Bian H, Lv Q, Huang XZ, Hu JL, Yang L, Mao BY. [Effects of Wenyang Huazhuo Tongluo Recipe Containing Serum on Transforming Growth Factor beta1/ Smad Signaling Pathway of Skin Fibroblasts in Systemic Sclerosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(9): 1054-9.
  6. Han L, Bian H, Ouyang J, Bi Y, Yang L, Ye S. Wenyang Huazhuo Tongluo formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis. BMC Complement Altern Med. 2016;16:69. https://doi.org/10.1186/s12906-016-1056-6
  7. Wang Q, Zang W, Han L, Yang L, Ye S, Ouyang J, et al. Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/beta-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model. Chin Med. 2018;13:17. https://doi.org/10.1186/s13020-018-0175-z
  8. Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis. BMC Complement Altern Med. 2014;14:224. https://doi.org/10.1186/1472-6882-14-224
  9. Wang Q, Shi G, Zhang Y, Lu F, Xie D, Wen C, et al. Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Sci Rep. 2019;9(1):355. https://doi.org/10.1038/s41598-018-36314-2
  10. Qi Q, Mao Y, Yi J, Li D, Zhu K, Cha X. Anti-fibrotic effects of Astragaloside IV in systemic sclerosis. Cell Physiol Biochem. 2014;34(6):2105-16. https://doi.org/10.1159/000366405
  11. Qi Q, Mao Y, Tian Y, Zhu K, Cha X, Wu M, et al. Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model. Am J Transl Res. 2017;9(3):1025-36.
  12. Liu Q, Lu J, Lin J, Tang Y, Pu W, Shi X, et al. Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis. Biomed Pharmacother. 2019;110:546-53. https://doi.org/10.1016/j.biopha.2018.12.016
  13. Jiang Y, Hu F, Li Q, Shen C, Yang J, Li M. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to- mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis. Int Immunopharmacol. 2019;77:105968. https://doi.org/10.1016/j.intimp.2019.105968
  14. Bian H, Yuan M, Gao Z-m, Bi XD, Han L, Hu JL, et al. [Effect of Wenyang Huazhuo Tongluo Recipe on Peripheral Blood Thl7/Treg Cell Balance in Systemic Sclerosis Patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(8):975-80.
  15. Zhou J, Yang D, Zhou SH, Wang JP, Liu YS, Wang SL. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial. Chin J Integr Med. 2018;24(3):185-92. https://doi.org/10.1007/s11655-017-2954-2
  16. Jang S, Yoon S, Ryu J, Lim J, Han S, Kim H, et al. A Case Report of Korean Traditional Medical Therapy on Gastric Dysmotility Involved in Patient with Systemic Sclerosis Sine Scleroderma. Korean J Orient Int Med. 2004;25(2):344-51.
  17. Liu XS, Gao Y, Zheng LW, Hua H. New alternative therapy for orofacial localized scleroderma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(3):e15-9.
  18. Kim MK, Jeong JG, Kim KM, Kim HJ, Kim JH, Kim YI, et al. The Effect of Korean Medical Treatment on Systemic Sclerosis : A Case Report. The Acupuncture. 2016;33(3):207-18. https://doi.org/10.13045/acupunct.2016048
  19. Jang Y, Kim J, Kim H, Lee G, Lim S. A Case of Raynaud's Syndrome Modified by Secondary Systemic Sclerosis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(4): 108-16. https://doi.org/10.6114/JKOOD.2018.31.4.108
  20. Park SH, Do TY, Lee SH, Lee JY. A Case Report of Clinical Effects of Complex Korean Medicine Treatment in Patients with Scleroderma Caused by Juvenile Idiopathic Arthritis. J Pediatr Korean Med. 2019;33(4):26-36.
  21. Kim H. Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. The Korean Journal of Medicine. 2014;87(4):395-400. https://doi.org/10.3904/kjm.2014.87.4.395
  22. Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castaneda AR, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int. 2019;2019:4569826. https://doi.org/10.1155/2019/4569826
  23. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-93. https://doi.org/10.1136/ard.62.11.1088
  24. Asano Y. Systemic sclerosis. J Dermatol. 2018;45(2):128-38. https://doi.org/10.1111/1346-8138.14153
  25. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-39. https://doi.org/10.1136/annrheumdis-2016-209909
  26. Oliver GF, Winkelmann RK. The current treatment of scleroderma. Drugs. 1989;37(1):87-96. https://doi.org/10.2165/00003495-198937010-00006
  27. Barsotti S, Orlandi M, Codullo V, Di Battista M, Lepri G, Della Rossa A, et al. One year in review 2019: systemic sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 119(4):3-14.
  28. Heo J. DongEuiBoGam. 1st ed. Seoul: Publisher DongEuiBoGam. 2006:1023.
  29. Editorial board of Traditional Korean Dermatology&Surgery. Text of Traditional Korean Dermatology & Surgery. 1st ed. Seoul: Seon Woo. 2007:484.
  30. Yang Y, Yang S, Chen M, Zhang X, Zou Y, Zhang X. Compound Astragalus and Salvia miltiorrhiza Extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J Ethnopharmacol. 2008;118(2):264-70. https://doi.org/10.1016/j.jep.2008.04.012
  31. Kim DH, Jung YS, Yoon M, Yoon Y, Shin SS. Analysis for Compatibility of Gyejibongnyeong-hwan and Its Biological Activities. Herbal Formula Science. 2016;24(4):353-65. https://doi.org/10.14374/HFS.2016.24.4.353
  32. Editorial board of Herbal Formula Science in Korean Medicine. Herbal Formula Science in Korean Medicine. 1st ed. Seoul: Koonja. 2020:998.
  33. Editorial board of Herbalogy. Herbalogy. 1st ed. Seoul: Younglimsa. 2004:210, 461, 580.
  34. Liu H, Wei W, Sun WY, Li X. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells. J Ethnopharmacol. 2009;122(3):502-8. https://doi.org/10.1016/j.jep.2009.01.035
  35. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int. 2007;51(6-7):361-9. https://doi.org/10.1016/j.neuint.2007.04.021
  36. Peng CH, Huang CN, Hsu SP, Wang CJ. Penta-acetyl geniposide-induced apoptosis involving transcription of NGF/p75 via MAPK-mediated AP-1 activation in C6 glioma cells. Toxicology. 2007;238(2-3):130-9. https://doi.org/10.1016/j.tox.2007.05.029
  37. Park JH, Yoon J, Lee KY, Park B. Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFbeta/Smad and ERK-MAPK signaling pathways. Biochimie. 2015;113:26-34. https://doi.org/10.1016/j.biochi.2015.03.015
  38. Yang K, Luo Y, Lu S, Hu R, Du Y, Liao P, et al. Salvianolic Acid B and Ginsenoside Re Synergistically Protect Against Ox-LDL-Induced Endothelial Apoptosis Through the Antioxidative and Antiinflammatory Mechanisms. Front Pharmacol. 2018;9:662. https://doi.org/10.3389/fphar.2018.00662
  39. Yu F, Lu Z, Chen B, Wu X, Dong P, Zheng J. Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated Patched1 methylation. J Cell Mol Med. 2015;19(11):2617-32. https://doi.org/10.1111/jcmm.12655
  40. Liu M, Xu H, Zhang L, Zhang C, Yang L, Ma E, et al. Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem Biophys Res Commun. 2018;495(1):325-31. https://doi.org/10.1016/j.bbrc.2017.11.014
  41. Luan L, Liang Z. Tanshinone IIA protects murine chondrogenic ATDC5 cells from lipopolysaccharide-induced inflammatory injury by down-regulating microRNA-203a. Biomed Pharmacother. 2018;103:628-36. https://doi.org/10.1016/j.biopha.2018.04.051
  42. Cao L, Huang B, Fu X, Yang J, Lin Y, Lin F. Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis. Mol Med Rep. 2017;15(6):4247-52. https://doi.org/10.3892/mmr.2017.6498
  43. Balanescu P, Balanescu E, Balanescu A. IL-17 and Th17 cells in systemic sclerosis: a comprehensive review. Rom J Intern Med. 2017;55(4):198-204. https://doi.org/10.1515/rjim-2017-0027
  44. Lee BW, Kim SC, Byun SH, Kim HK, Jee SY. Study on Duties and Abilities of a Human's Mentality[five kinds of mental activities]-Oriental Medicine's Outlook on Mentality-. J Korean Med Classics. 2004;17(1): 198-217.